Mercy Hospital St. Louis is offering a clinical trial for an investigational device called the BAROSTIM NEO®. The BeAT-HF (Baroreflex Activation Therapy® for Heart Failure) clinical trial will determine if the investigational BAROSTIM NEO implantable device helps patients live longer, reduces heart failure-related hospitalizations, improves quality of life and is safe. It stimulates special cells in the arteries of the neck called baroreceptors to signal the heart, kidneys and blood vessels that may improve heart function and reduce heart failure symptoms.